glp 1 side effects sex drive Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don't 'see' it The Good, The Bad and

And you may start to see patternsnot just on the scale, but in how your body feels, how your energy shifts, and how your relationship with your health is changing

Sean Arora, MD - a board-certified physician licensed in all 50 states and the founder and CEO of Arora Health

Akbari C, Dodd M, Stl P, et al

Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity, and Aetna's 6947-C policy covers that use on its own criteria: "an apnea-hypopnea index (AHI) of at least 15 events per hour on polysomnography or home sleep apnea test" plus a current BMI of 30 or higher

Across randomized cardiovascular outcome trials and meta-analyses, SGLT2 inhibitors consistently reduce hospitalization for heart failure by approximately 3037% (hazard ratio [HR] 0.630.70), with benefits observed regardless of prior atherosclerotic cardiovascular disease status [6, 23]